Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer.

ABSTRACT:

Background

Systemic inflammation is currently regarded as a hallmark of cancer. This study aimed to accurately clarify the prognostic value of various inflammatory markers in patients with stage IV cancer.

Methods

This study assessed 2,424 patients with cancer diagnosed with cancer in tumor, node, metastasis (TNM) stage IV. After evaluating the predictive value of 13 inflammatory indicators for patient prognosis using the C index, the lymphocyte C-reactive protein ratio (LCR) was selected to elucidate the prognostic and predictive values in patients with stage IV cancer. Kaplan-Meier and Cox proportional hazards regression models were used to analyze long-term survival.

Results

A total of 1,457 men (60.1%) and 967 women (39.9%) diagnosed with TNM stage IV cancer were

SUBMITTER: Zhang HY 

PROVIDER: S-EPMC9585763 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature